Prelude Therapeutics Inc — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Pierce Christopher | EVP and Chief of Business Oper | Sale | 3,295 | $40.29 | $132,756 | 3,750 | Apr 29, 2021 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Option Exercise | 3,223 | $1.89 | $6,091 | 3,667 | Apr 29, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 1,711 | $36.11 | $61,784 | — | Apr 27, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 4,000 | $31.27 | $125,080 | — | Apr 19, 2021 |
| Scherle Peggy | Chief Scientific Officer | Sale | 669 | $38.97 | $26,071 | 174,589 | Apr 8, 2021 |
| Pierce Christopher | EVP and Chief of Business Oper | Sale | 200 | $40.00 | $8,000 | 3,750 | Apr 8, 2021 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Sale | 100 | $40.00 | $4,000 | 444 | Apr 8, 2021 |
| Mauro David J | Chief Medical Officer | Sale | 3,274 | $37.04 | $121,269 | 6,343 | Apr 8, 2021 |
| Scherle Peggy | Chief Scientific Officer | Award / Grant | 15,370 | $1.43 | $21,979 | 188,290 | Apr 7, 2021 |
| Pierce Christopher | EVP and Chief of Business Oper | Sale | 828 | $40.08 | $33,186 | 3,750 | Apr 7, 2021 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Option Exercise | 1,000 | $1.89 | $1,890 | 1,444 | Apr 7, 2021 |
| Mauro David J | Chief Medical Officer | Option Exercise | 15,383 | $1.89 | $29,074 | 15,383 | Apr 7, 2021 |
| BAKER BROS. ADVISORS LP | — | Option Exercise | 5,188 | $12.85 | $66,666 | 876,061 | Jan 27, 2021 |
| FRIEDMAN PAUL A | — | C | 295,794 | — | — | 347,522 | Sep 29, 2020 |
| Bonita David P | — | Purchase | 526,300 | $19.00 | $9,999,700 | 526,300 | Sep 29, 2020 |
| Baker Bros. Advisors (GP) LLC | — | Purchase | 104,628 | $19.00 | $1,987,932 | 870,873 | Sep 29, 2020 |
| Combs Andrew | EVP, Head of Chemistry | Purchase | 1,000 | $19.00 | $19,000 | 260,380 | Sep 29, 2020 |
| Dier Mardi | — | Purchase | 10,000 | $19.00 | $190,000 | 10,000 | Sep 29, 2020 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Purchase | 444 | $19.00 | $8,436 | 444 | Sep 29, 2020 |
| Pierce Christopher | EVP and Chief of Business Oper | Purchase | 3,750 | $19.00 | $71,250 | 3,750 | Sep 29, 2020 |
| Vaddi Krishna | President, CEO | C | 32,876 | — | — | 551,774 | Sep 29, 2020 |
| ORBIMED ADVISORS LLC | — | Purchase | 526,300 | $19.00 | $9,999,700 | 526,300 | Sep 25, 2020 |